TrialCancer immunology, immunotherapy : CII2023

Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

Jeffrey S Weber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.